截至2025年8月8日 10:49，中证中药指数(930641)上涨0.48%，成分股众生药业(002317)上涨6.44%，亚 宝药业(600351)上涨3.74%，千金药业(600479)上涨2.59%，方盛制药(603998)上涨1.49%，红日药业 (300026)上涨1.45%。中药ETF(159647)上涨0.49%，最新价报1.04元。 8月5日到7日，中药板块持续进行调整，但获资金逆市买入。中药ETF近3天获得连续资金净流入，最高 单日获得980.70万元净流入，合计"吸金"2020.76万元，日均净流入达673.59万元。 消息面上，中药饮片标签新规落地，江海证券指出，新规的实施使得中药饮片生产企业需要投入更多资 源用于确定保质期的研究工作。这增加了中小企业的成本负担，因为它们可能缺乏相应的科研能力与资 金实力。而头部企业凭借自身强大的研发团队、完善的质量控制体系以及充足的资金，能够更好地适应 这一要求。此前由于部分中药饮片未标注保质期，市场上存在一些以次充好、产品质量参差不齐的现 象。随着保质期标注的强制实施，一些无法满足合规要求的小作坊式企业将逐渐被市场淘汰，从而净化 市场环境。头部企业 ...

Core Viewpoint - The Chinese traditional medicine industry is entering a new phase characterized by a significant transformation due to the implementation of centralized procurement, which is expected to impact the entire industry chain from cultivation to distribution and production [1][2]. Group 1: Market Performance - As of June 3, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) increased by 0.84%, with notable gains from companies such as Huawen Pharmaceutical (002907) up 8.87% and Zuo Li Pharmaceutical (300181) up 8.67% [1]. - The Traditional Chinese Medicine ETF (159647) rose by 0.61%, marking its third consecutive increase, with a latest price of 1 yuan [1]. - Over the week leading up to May 30, 2025, the Traditional Chinese Medicine ETF saw a cumulative increase of 2.17%, ranking first among comparable funds [1]. Group 2: Industry Developments - In May, the implementation of centralized procurement for traditional Chinese medicine pieces accelerated, with approximately 10 provinces beginning to implement the results of the first national centralized procurement [1]. - Some winning companies reported overwhelming orders and have raised their operational targets for the year, reflecting a generally optimistic outlook for their performance [1]. - Industry insiders noted that the changes brought by centralized procurement are causing significant disruptions across the entire traditional Chinese medicine supply chain, akin to a "butterfly effect" [1]. Group 3: Investment Insights - Guosen Securities suggests that the traditional Chinese medicine industry is entering a favorable investment phase due to supply-side structural reforms and demand policy stimulation, emphasizing the importance of matching valuation with sustainable performance [2]. - The Zhongzheng Traditional Chinese Medicine Index includes companies involved in the production and sales of traditional Chinese medicine, reflecting the overall performance of the sector [2]. - As of May 30, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.6% of the index, including major players like Yunnan Baiyao (000538) and Pianzaihuang (600436) [2].